<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">16354012</PMID>
        <DateCompleted>
            <Year>2006</Year>
            <Month>04</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1530-9932</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Oct</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>AAPS PharmSciTech</Title>
                <ISOAbbreviation>AAPS PharmSciTech</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E513-22</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The present investigation aimed at formulation, performance evaluation, and stability studies of new vesicular drug carrier system protransfersomes for transdermal delivery of the contraceptive agent, levonorgestrel. Protransfersome gel (PTG) formulations of levonorgestrel were prepared and characterized for vesicle shape, size, entrapment efficiency, turbidity, and drug permeation across rat skin and were evaluated for their stability. The system was evaluated in vivo for biological assay of progestational activity including endometrial assay, inhibition of the formation of corpora lutea, and weight gain of uterus. The effects of different formulation variables (type of alcohol, type and concentration of surfactant) on transdermal permeability profile were assessed. The optimized PTG formulation showed enhanced in vitro skin permeation flux of 15.82 +/- 0.37 microg/cm2/hr as compared to 0.032 +/- 0.01 microg/cm2/hr for plain drug solution. PTG also showed good stability and after 2 months of storage there was no change in liquid crystalline nature, drug content, and other characteristic parameters. The peak plasma concentration of levonorgestrel (0.139 +/- 0.05 microg/mL) was achieved within 4 hours and maintained until 48 hours by a single topical application of optimized PTG formulation. In vivo performance of the PTG formulation showed increase in the therapeutic efficacy of drug. Results indicated that the optimized protransfersomal formulation of levonorgestrel had better skin permeation potential, sustained release characteristic, and better stability than proliposomal formulation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Subheet</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sapre</LastName>
                    <ForeName>Rachna</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tiwary</LastName>
                    <ForeName>Ashok K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Narendra K</ForeName>
                    <Initials>NK</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>AAPS PharmSciTech</MedlineTA>
            <NlmUniqueID>100960111</NlmUniqueID>
            <ISSNLinking>1530-9932</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5W7SIA7YZW</RegistryNumber>
                <NameOfSubstance UI="D016912">Levonorgestrel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016912" MajorTopicYN="N">Levonorgestrel</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018583" MajorTopicYN="N">Pliability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16354012</ArticleId>
            <ArticleId IdType="doi">10.1208/pt060364</ArticleId>
            <ArticleId IdType="pmc">PMC2750398</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Adv Drug Deliv Rev. 2002 Nov 1;54 Suppl 1:S31-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12460714</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2002 Aug 19;1564(1):21-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12100992</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Dev Ind Pharm. 2003 Oct;29(9):1013-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14606665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Drug Deliv. 2005 Jul;2(3):223-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16305424</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biomater Appl. 1997 Jul;12(1):77-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9285331</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Control Release. 2002 Aug 21;82(2-3):223-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12175739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 1992 Feb 17;1104(1):226-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1550849</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Pharm. 2000 Feb 25;196(1):63-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10675708</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharm Pharmacol. 1991 Mar;43(3):154-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1675270</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anal Biochem. 1978 Oct 15;90(2):809-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">727510</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Control Release. 2003 Jan 9;86(1):145-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12490380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 1998 Apr 22;1371(1):31-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9565654</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1995 Oct;52(4):4198-4208</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9963891</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Control Release. 1999 Mar 29;58(2):207-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10053193</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Pharm. 2002 Jan 31;232(1-2):163-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11790500</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 1990 Feb 28;1022(2):171-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2306453</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Dev Ind Pharm. 1998 Jul;24(7):631-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9876507</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Control Release. 1998 Jul 31;54(2):149-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9724902</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
